Research By Ebb Therapeutics® Published In The Journal Sleep
PITTSBURGH, Sept. 8, 2020 /PRNewswire/ -- Ebb Therapeutics ("Ebb"), a sleep tech company specializing in drug-free, wearable solutions to sleeplessness, today announced that the abstracts of four studies piloted by its founder and chief medical officer, Dr. Eric Nofzinger, have been published in the 2020 Abstract Supplement of SLEEP, the official publication of the Sleep Research Society. The edition features research accepted at the Virtual SLEEP 2020 Meeting (August 27-30), the 34th annual meeting of the Associated Professional Sleep Societies. The studies validate the effects of forehead cooling on subjects with sleeplessness and insomnia - including two unique sets: menopausal women and veterans - and are titled as follows:
This new data supplements Ebb's prior scientific research, including multiple peer-reviewed publications and previous SLEEP meeting abstracts. These include the results of Ebb's randomized, controlled clinical trial in insomnia patients that led to a publication in Journal SLEEP in May 2018 ("A Novel Forehead Temperature-Regulating Device for Insomnia: A Randomized Clinical Trial" – T. Roth et. al.)."
All of the data is based on more than 35 years of brain-imaging research during Nofzinger's tenure as Director of the Sleep Neuroimaging Research Program at the University of Pittsburgh School of Medicine. Nofzinger discovered that when the forehead is cooled there is a reduction in activity in the frontal cortex and a person is better able to reach restorative sleep. He dubbed this "PrecisionCool Technology™" and spent more than a decade developing a wearable forehead-cooling device to help patients with insomnia.
"Without good sleep, one's quality of life suffers," said Nofzinger. "It has been my goal for three decades to bring a safe sleep solution to the masses, and I am proud to be able to have data to show that precise forehead cooling is truly effective."
In 2019, Ebb Therapeutics brought to market the first and only solution that uses precise cooling to reduce metabolic activity in the frontal cortex of the brain: the Ebb CoolDrift™ Luxe™, a scientifically-engineered fluid-filled headband that softly wraps around the head and cools the forehead to the optimal temperature range, calming the mind and allowing the body to fall asleep naturally. In August 2020, the company launched a second-generation, ultra-versatile version of the device: the CoolDrift™ Versa™.
About Ebb Therapeutics:
View original content to download multimedia:http://www.prnewswire.com/news-releases/research-by-ebb-therapeutics-published-in-the-journal-sleep-301125780.html
SOURCE Ebb Therapeutics Inc.